Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences initiated a Phase 1 first-in-human study for NBIP-'2118, an investigational CRF(2) receptor agonist designed to treat obesity while preserving lean mass. The study will evaluate safety and tolerability in healthy, overweight, and obese adults, with initial data anticipated in 2027.
Key figures
- Drug Name
- NBIP-'2118
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.